Indatuximab ravtansine

From WikiMD's Wellnesspedia

Indatuximab ravtansine is a monoclonal antibody designed for the treatment of cancer. This drug was developed by ImmunoGen.

Mechanism of Action[edit | edit source]

Indatuximab ravtansine is a monoclonal antibody that targets the CD138 antigen, a protein that is overexpressed in multiple myeloma cells. The drug is linked to a cytotoxic agent, maytansinoid, which is released into the cancer cell upon binding to the CD138 antigen. This leads to cell death and reduction in tumor size.

Clinical Trials[edit | edit source]

Indatuximab ravtansine has been studied in several clinical trials for the treatment of multiple myeloma. In a phase II study, the drug showed promising results in patients with relapsed or refractory multiple myeloma.

Side Effects[edit | edit source]

Common side effects of indatuximab ravtansine include fatigue, nausea, and diarrhea. Serious side effects can include neutropenia, anemia, and thrombocytopenia.

See Also[edit | edit source]

References[edit | edit source]


Indatuximab ravtansine Resources

Find a healthcare provider anywhere in the world quickly and easily!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD